| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A rare case of osteoblastoma from medieval Tuscany
|
Riccomi, Giulia
|
|
|
19 |
1 |
p. 26
|
artikel
|
| 2 |
A rare location of palpebral rhabdomyosarcoma
|
Essafi, Hafssa
|
|
|
19 |
1 |
p. e65
|
artikel
|
| 3 |
2017 ASH Meeting
|
Yaqub, Farhat
|
|
|
19 |
1 |
p. 21
|
artikel
|
| 4 |
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
|
Patel, Manish R
|
|
|
19 |
1 |
p. 51-64
|
artikel
|
| 5 |
BGJ398 for FGFR-altered advanced cholangiocarcinoma
|
Gilbert, Judith A
|
|
|
19 |
1 |
p. e16
|
artikel
|
| 6 |
Bipolar androgen therapy: an intriguing paradox
|
Evans, Christopher P
|
|
|
19 |
1 |
p. 8-10
|
artikel
|
| 7 |
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
|
Teply, Benjamin A
|
|
|
19 |
1 |
p. 76-86
|
artikel
|
| 8 |
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Di Leo, Angelo
|
|
|
19 |
1 |
p. 87-100
|
artikel
|
| 9 |
Carfilzomib for relapsed or refractory multiple myeloma
|
Tanimoto, Tetsuya
|
|
|
19 |
1 |
p. e1
|
artikel
|
| 10 |
Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply
|
Dimopoulos, Meletios A
|
|
|
19 |
1 |
p. e2
|
artikel
|
| 11 |
CAR T-cell therapy in refractory large B-cell lymphoma
|
Stirrups, Robert
|
|
|
19 |
1 |
p. e19
|
artikel
|
| 12 |
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study
|
Herbst, Roy S
|
|
|
19 |
1 |
p. 101-114
|
artikel
|
| 13 |
Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
|
Alexander, Brian M
|
|
|
19 |
1 |
p. e33-e42
|
artikel
|
| 14 |
Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
|
Camidge, D Ross
|
|
|
19 |
1 |
p. e20-e32
|
artikel
|
| 15 |
Combined androgen blockade for salivary gland carcinoma
|
Gourd, Elizabeth
|
|
|
19 |
1 |
p. e17
|
artikel
|
| 16 |
Complexity of intermittent letrozole adjuvant therapy
|
Chlebowski, Rowan T
|
|
|
19 |
1 |
p. 13-15
|
artikel
|
| 17 |
Complications during minimal invasive thoracic surgery: are new surgeons prepared?
|
Cypel, Marcelo
|
|
|
19 |
1 |
p. 17-19
|
artikel
|
| 18 |
Correction to Lancet Oncol 2017; 18: 1493–501
|
|
|
|
19 |
1 |
p. e8
|
artikel
|
| 19 |
Correction to Lancet Oncol 2017; 18: 1565–66
|
|
|
|
19 |
1 |
p. e8
|
artikel
|
| 20 |
Dacomitinib in NSCLC: a positive trial with little clinical impact
|
Addeo, Alfredo
|
|
|
19 |
1 |
p. e4
|
artikel
|
| 21 |
Dacomitinib in NSCLC: a positive trial with little clinical impact – Authors' reply
|
Wu, Yi-Long
|
|
|
19 |
1 |
p. e5
|
artikel
|
| 22 |
Durvalumab boosts progression-free survival in NSCLC
|
Gourd, Elizabeth
|
|
|
19 |
1 |
p. e11
|
artikel
|
| 23 |
Early HER2-positive breast cancers: time for a new revolution?
|
Gligorov, Joseph
|
|
|
19 |
1 |
p. 12-13
|
artikel
|
| 24 |
EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation
|
Pirker, Robert
|
|
|
19 |
1 |
p. 10-12
|
artikel
|
| 25 |
Embracing the imperfect: new beginnings after cancer
|
Lucas, Catherine
|
|
|
19 |
1 |
p. 25
|
artikel
|
| 26 |
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
|
Colleoni, Marco
|
|
|
19 |
1 |
p. 127-138
|
artikel
|
| 27 |
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
|
Zhong, Wen-Zhao
|
|
|
19 |
1 |
p. 139-148
|
artikel
|
| 28 |
Identifying precursor lesions of pancreatic cancer
|
Venkatesan, Priya
|
|
|
19 |
1 |
p. e13
|
artikel
|
| 29 |
Implementation of a community-based breast cancer management programme
|
Málaga, Germán
|
|
|
19 |
1 |
p. e3
|
artikel
|
| 30 |
Introduction to the Yale Precision Medicine Tumor Board
|
Cecchini, Michael
|
|
|
19 |
1 |
p. 19-20
|
artikel
|
| 31 |
131I radiation exposure and thyroid cancer
|
Burki, Talha Khan
|
|
|
19 |
1 |
p. e9
|
artikel
|
| 32 |
JAVELIN: avelumab another spear to fight urothelial carcinoma
|
Lalani, Aly-Khan A
|
|
|
19 |
1 |
p. 5-7
|
artikel
|
| 33 |
Lenalidomide plus dexamethasone in multiple myeloma
|
Das, Manjulika
|
|
|
19 |
1 |
p. e12
|
artikel
|
| 34 |
Leptomeningeal metastases in non-small-cell lung cancer
|
Cheng, Haiying
|
|
|
19 |
1 |
p. e43-e55
|
artikel
|
| 35 |
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
|
|
|
|
19 |
1 |
p. 27-39
|
artikel
|
| 36 |
Lung cancer's real adjuvant EGFR targeted therapy questions
|
Ng, Terry L
|
|
|
19 |
1 |
p. 15-17
|
artikel
|
| 37 |
Neoadjuvant chemotherapy in breast cancer: more than just downsizing
|
Derks, Marloes G M
|
|
|
19 |
1 |
p. 2-3
|
artikel
|
| 38 |
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
|
Hurvitz, Sara A
|
|
|
19 |
1 |
p. 115-126
|
artikel
|
| 39 |
Osimertinib improves progression-free survival in NSCLC
|
Stirrups, Robert
|
|
|
19 |
1 |
p. e10
|
artikel
|
| 40 |
PD-1 inhibition in sarcoma still needs investigation
|
Toulmonde, Maud
|
|
|
19 |
1 |
p. e6
|
artikel
|
| 41 |
PD-1 inhibition in sarcoma still needs investigation – Authors’ reply
|
Tawbi, Hussein A
|
|
|
19 |
1 |
p. e7
|
artikel
|
| 42 |
Perspectives: call for papers
|
del Pozo Martín, Yaiza
|
|
|
19 |
1 |
p. 19
|
artikel
|
| 43 |
San Antonio Breast Cancer Symposium 2017
|
Nelson, Roxanne
|
|
|
19 |
1 |
p. 22
|
artikel
|
| 44 |
Soft-tissue sarcoma risk in childhood cancer survivors
|
Das, Manjulika
|
|
|
19 |
1 |
p. e15
|
artikel
|
| 45 |
Systematic review of health-related quality of life and patient-reported outcome measures in gestational trophoblastic disease: a parallel synthesis approach
|
Ireson, Jane
|
|
|
19 |
1 |
p. e56-e64
|
artikel
|
| 46 |
TAS-102 in metastatic colorectal cancer
|
Burki, Talha Khan
|
|
|
19 |
1 |
p. e18
|
artikel
|
| 47 |
The NHS: failing to deliver on Beveridge's promise?
|
The Lancet Oncology,
|
|
|
19 |
1 |
p. 1
|
artikel
|
| 48 |
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
|
Denkert, Carsten
|
|
|
19 |
1 |
p. 40-50
|
artikel
|
| 49 |
Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance
|
Salgado, Roberto
|
|
|
19 |
1 |
p. 3-5
|
artikel
|
| 50 |
Upfront resection of pancreatic intraductal neoplasms
|
Gourd, Elizabeth
|
|
|
19 |
1 |
p. e14
|
artikel
|
| 51 |
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib
|
Mauro, Francesca R
|
|
|
19 |
1 |
p. 7-8
|
artikel
|
| 52 |
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
|
Jones, Jeffrey A
|
|
|
19 |
1 |
p. 65-75
|
artikel
|
| 53 |
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes
|
Cecchini, Michael
|
|
|
19 |
1 |
p. 23-24
|
artikel
|
Tijdschrift beschrijving